Published in J Neuropathol Exp Neurol on October 01, 2002
VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A (2009) 2.25
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest (2012) 1.90
Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol (2008) 1.44
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 1.38
White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci (2009) 1.18
CD8 T cell-initiated vascular endothelial growth factor expression promotes central nervous system vascular permeability under neuroinflammatory conditions. J Immunol (2009) 1.17
Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem (2011) 1.16
Alterations in blood-brain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2005) 1.04
Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol (2007) 1.02
Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br J Pharmacol (2008) 1.01
Acute demyelinating lesions with restricted diffusion in multiple sclerosis. Mult Scler (2012) 0.99
Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation (2010) 0.97
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol Commun (2014) 0.92
Mesenchymal stem cells stabilize the blood-brain barrier through regulation of astrocytes. Stem Cell Res Ther (2015) 0.88
Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med (2009) 0.87
The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS One (2011) 0.86
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection. Am J Transl Res (2014) 0.85
Sustained expression of vascular endothelial growth factor and angiopoietin-1 improves blood-spinal cord barrier integrity and functional recovery after spinal cord injury. J Neurotrauma (2010) 0.84
Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions. Brain (2015) 0.84
Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology. J Neurol (2014) 0.84
Inhibition of Vascular Endothelial Growth Factor Receptor 2 Exacerbates Loss of Lower Motor Neurons and Axons during Experimental Autoimmune Encephalomyelitis. PLoS One (2016) 0.82
Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation (2007) 0.82
Metabolism and regional cerebral blood volume in autoimmune inflammatory demyelinating lesions mimicking malignant gliomas. J Neurol (2010) 0.81
Plasma biomarkers discriminate clinical forms of multiple sclerosis. PLoS One (2015) 0.80
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair. Biomed Res Int (2014) 0.79
Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis. Mol Med (2008) 0.79
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling. Acta Neuropathol (2015) 0.78
Upregulation of vascular endothelial growth factor receptor-3 in the spinal cord of Lewis rats with experimental autoimmune encephalomyelitis. J Histochem Cytochem (2012) 0.77
Extensive vascular remodeling in the spinal cord of pre-symptomatic experimental autoimmune encephalomyelitis mice; increased vessel expression of fibronectin and the α5β1 integrin. Exp Neurol (2013) 0.76
The role of angiogenesis in the pathology of multiple sclerosis. Vasc Cell (2014) 0.76
VEGF receptor antagonist Cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult. J Neuroinflammation (2008) 0.76
Hypertonic saline alleviates experimentally induced cerebral oedema through suppression of vascular endothelial growth factor and its receptor VEGFR2 expression in astrocytes. BMC Neurosci (2016) 0.76
Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3). PLoS One (2014) 0.76
Vascular pathology in multiple sclerosis: mind boosting or myth busting? Exp Transl Stroke Med (2011) 0.76
Glial regulation of the blood-brain barrier in health and disease. Semin Immunopathol (2015) 0.75
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome? Curr Neuropharmacol (2015) 0.75
Imag(in)ing multiple sclerosis: Time to take better pictures. J Neuroimmunol (2016) 0.75
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients. Clin Exp Med (2014) 0.75
Blockade of the kinin B1 receptor affects the cytokine/chemokine profile in rat brain subjected to autoimmune encephalomyelitis. Inflammopharmacology (2017) 0.75
Protective effects on the retina after ranibizumab treatment in an ischemia model. PLoS One (2017) 0.75
von Hippel-Lindau disease. Lancet (2003) 6.20
Prevention of intraoperative cerebrospinal fluid leaks by lumbar cerebrospinal fluid drainage during surgery for pituitary macroadenomas. J Neurosurg (2012) 3.35
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
Posterior subtemporal transtentorial approach to intraparenchymal lesions of the anteromedial region of the superior cerebellum. J Neurosurg (2005) 2.69
Pathophysiology of persistent syringomyelia after decompressive craniocervical surgery. Clinical article. J Neurosurg Spine (2010) 2.49
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades 0-2 nonfunctioning pituitary macroadenomas at a single institution. J Neurosurg (2014) 2.13
Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine (2012) 1.92
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol (2009) 1.75
Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA (2007) 1.73
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg (2011) 1.64
Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg (2009) 1.61
Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2006) 1.58
Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg (2006) 1.55
Intraoperative infrared functional imaging of human brain. Ann Neurol (2003) 1.54
Dysregulation of TGF-beta signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease. Blood (2008) 1.53
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis (2003) 1.51
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg (2003) 1.48
Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest (2005) 1.46
Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology (2008) 1.45
Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab (2003) 1.44
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med (2004) 1.38
The history of pituitary surgery for Cushing disease. J Neurosurg (2011) 1.38
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res (2003) 1.38
Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg (2002) 1.35
Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res (2006) 1.34
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol (2013) 1.33
Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med (2007) 1.32
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg (2005) 1.31
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg (2003) 1.30
Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood (2004) 1.29
Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab (2005) 1.24
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog (2006) 1.24
Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res (2006) 1.23
Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.23
Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol (2005) 1.23
Reduced Foxp3 protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. J Infect Dis (2006) 1.22
Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. J Neurovirol (2014) 1.22
Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.21
Pathophysiology of headache associated with cough in patients with Chiari I malformation. J Neurosurg (2003) 1.20
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One (2011) 1.19
Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood (2011) 1.18
Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 1.18
Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg (2004) 1.17
Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. J Cell Physiol (2002) 1.17
Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg (2005) 1.17
N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 1.17
Effect of ependymal and pial surfaces on convection-enhanced delivery. J Neurosurg (2008) 1.17
Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg (2007) 1.17
Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One (2009) 1.15
Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci (2004) 1.14
Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg (2005) 1.13
Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J Neurovirol (2005) 1.12
Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis (2006) 1.12
Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab (2009) 1.11
Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res (2005) 1.11
Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg (2007) 1.11
Neuroimmunity of HTLV-I Infection. J Neuroimmune Pharmacol (2010) 1.11
Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. Herpes (2005) 1.11
Human herpes virus 6B: a possible role in epilepsy? Epilepsia (2008) 1.10
Pituitary stalk hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2009) 1.10
Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J Virol (2006) 1.09
Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res (2005) 1.09
In vivo quantification of T₂ anisotropy in white matter fibers in marmoset monkeys. Neuroimage (2011) 1.08
Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol (2005) 1.08
Retrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-I-associated neurologic disease. Blood (2008) 1.07
GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J Virol (2006) 1.07
Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat Med (2003) 1.06
Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2008) 1.06
Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol (2010) 1.05
Comparative proteomic profiles of meningioma subtypes. Cancer Res (2006) 1.05
Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol (2005) 1.05
Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One (2008) 1.05
Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg (2002) 1.04
Time course of syringomyelia resolution following decompression of Chiari malformation Type I. J Neurosurg Pediatr (2008) 1.03
HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J Clin Invest (2006) 1.03
Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol (2005) 1.03
Selective ablation of nociceptive neurons for elimination of hyperalgesia and neurogenic inflammation. J Neurosurg (2005) 1.03
Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease. J Clin Endocrinol Metab (2005) 1.03
Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol (2010) 1.03
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci (2009) 1.02
Infratentorial craniospinal irradiation for von Hippel-Lindau: a retrospective study supporting a new treatment for patients with CNS hemangioblastomas. Neuro Oncol (2011) 1.02
Cushing's syndrome due to a pituitary corticotropinoma in a child with tuberous sclerosis: an association or a coincidence? Clin Endocrinol (Oxf) (2007) 1.02
Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res (2005) 1.02
Endolymphatic sac tumor demonstrated by intralabyrinthine hemorrhage. Case report. J Neurosurg (2007) 1.02